Patients under 21 with breast or colorectal cancer more likely to have aggressive disease
the ONA take:
According to two studies presented at the 2014 Clinical Congress of the American College of Surgeons in San Francisco, California, when breast and colorectal cancers occur in children, the diseases are aggressive.
Researchers at Seattle Children's Hospital in Seattle, Washington sought to investigate how breast cancer progresses when diagnosed in patients under age 21. Researchers identified 574 patients aged 21 or younger with breast cancer from the National Cancer Data Base of the American College of Surgeons and American Cancer Society. Results showed that younger patients were more likely to be African American, male, and uninsured.
Furthermore, these patients had worse outcomes that adult patients. Researchers also found a large delay between surgical treatment and radiation therapy. The delay is something the researchers hope to investigate further.
The other study was conducted by researchers at the Maine Medical Center in Portland, Maine who wanted to assess the outcomes of younger patients diagnosed with colorectal cancer. They identified 920 patients age 21 or younger. They found that younger patients were more likely diagnosed with advanced disease and found to have more aggressive tumors. Pediatric patients also had lower 5-year survival rates compared young adults.
When breast and colorectal cancers occur in children, the diseases are aggressive.
Breast and colorectal cancers rarely occur in children, but when they do, these conditions are more precarious, according to a pair of National Cancer Data Base (NCDB) studies presented this week at the 2014 Clinical Congress of the American College of Surgeons. Both breast cancer and colon cancer are known as adult conditions.
According to the American Cancer Society, 95 percent of new breast cancer cases occur in women age 40 and older. Colorectal cancer is also largely an adult cancer, with 90 percent of cases occurring in people who are age 50 and older.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|